News

Mark Kotter wins in two categories, Equity-Backed Entrepreneur of the Year and Purpose Entrepreneur of the Year, at the Great Brit...

Lead candidate is encapsulated allogeneic txHepatocytes for treatment of acute liver failure, SAB expanded to include 3 global exp...

bit.bio launches first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease m...

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...